← Leaderboards
Ruby F. Meredith
University Of Alabama At Birmingham
$400,090
Attributed
$400,090
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.2K · FY2005–07$10K$7.5K$5K$2.5K$0
'05
'06
'07
Funding mix
By agency
NIH$400,090 · 7
By mechanism
M01$400,090 · 6
P50$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Steven Mark Rowe$18,443,646
- Bradford Alan Woodworth$3,946,767
- Susan Elizabeth Birket$3,710,278
- Ralph R Weichselbaum$16,065,057
- George Martin Solomon$1,723,350
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationRecombinant ProteinsClinical ResearchHuman SubjectDosageNeoplasm /Cancer Radiation TherapyBiotinMetastasisNonhuman Therapy EvaluationIndiumBinding ProteinsChimeric ProteinsNeoplasm /Cancer ChemotherapyClinical Trial Phase IFibroblast Growth FactorInflammationAthymic MouseCombination TherapyAntitumor AntibodyHead /Neck NeoplasmClinical TrialsFemaleBreast NeoplasmsMucus
Grant awards (13)
C225 WITH CHEMORADIATION FOR POST-OP HEAD AND NECK SQUAMOUS CELL CANCER$5,536
M01 · FY2007 · RR · contact PI
90Y-ZEVALIN RADIOIMMUNOTHERAPY USING A MODIFIED TREATMENT REGIMEN FOR RELAPSED O$1,384
M01 · FY2007 · RR · contact PI
C225 WITH CHEMORADIATION FOR NSCLC$3,055
M01 · FY2006 · RR · contact PI
C225 WITH CHEMORADIATION FOR POST-OP HEAD AND NECK SQUAMOUS CELL CANCER$2,585
M01 · FY2006 · RR · contact PI
UAB 9846 PHASE I TRIAL OF 131I-HUCC49DCH2 FOR COLON CANCER$244
M01 · FY2006 · RR · contact PI
C225 WITH CHEMORADIATION FOR NSCLC$4,497
M01 · FY2005 · RR
UAB 9846 PHASE I TRIAL OF 131I-HUCC49DCH2 FOR COLON CANCER$2,748
M01 · FY2005 · RR
RECOMBINANT KERATINOCYTE GROWTH FACTOR IN HEAD &NECK CANCER$175,256
M01 · FY2002 · RR
PRETARGETING RADIOIMMUNOTHERAPY OF METASTATIC BREAST$0
P50 · FY2002 · CA
RECOMBINANT KERATINOCYTE GROWTH FACTOR IN HEAD &NECK CANCER$175,256
M01 · FY2001 · RR
PRETARGETING RADIOIMMUNOTHERAPY OF METASTATIC BREAST$0
P50 · FY2001 · CA
RECOMBINANT KERATINOCYTE GROWTH FACTOR IN HEAD &NECK CANCER$29,529
M01 · FY2000 · RR
PRETARGETING RADIOIMMUNOTHERAPY OF METASTATIC BREAST$0
P50 · FY2000 · CA